CTRI/2024/02/063282尚未招募4 期
An open label, single-centric, non-randomized clinical study to evaluate the safety and efficacy of a new antimicrobial wound dressing (VELVERT) as an adjuvant therapy in patients having Necrotising soft-tissue infections (NSTI)/ fasciitis - Nil
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1.Adult male or female subjects within the age group of 18 to 70 years (both inclusive).
- •2.Subject with HbA1c level below 6.5 % (Well-controlled diabetes mellitus)
- •3.Subject with soft tissue infection caused by trauma, injury, burn, surgery.
- •4.Subjects with damaged deep layers of your skin that led to necrosis.
排除标准
- •Exclusion Criteria
- •1.Subject unwilling or unable to comply with the follow up visits necessary for data collection.
- •2.Subject found positive for HIV, HBsAg and HCV.
- •3.Concurrent participation in another clinical trial that involves an investigational drug or dressing that would interfere with this study.
- •4.Pregnant females.
- •5.Subject with Immunosuppression, corticosteroids or chemotherapy.
- •6.Subject with decision making impairment.
- •7.Allergies to any material contained investigational devices.
研究者
相似试验
尚未招募
3 期
The implantable tissues intended for human recipients for correcting cardiovascular abnormalitiesCTRI/2017/08/009225Frontier Lifeline Hospital
已完成
不适用
A single-center, non-randomized, open-label, one-sequence, two-period within-subject study to investigate the effect of Rifampicin on the pharmacokinetics of multiple doses of Balovaptan in healthy volunteersNL-OMON46088PRA Health F. Hoffmann-La Roche Ltd16
进行中（未招募）
不适用
Continuation of cholic acid treatment for people with bile acid disorders who have previously taken part in clinical trials of cholic acid capsules.Patients with inborn errors of bile acid synthesis and metabolismMedDRA version: 14.0Level: PTClassification code 10070882Term: Inborn error in primary bile acid synthesisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-004528-36-Outside-EU/EEAAsklepion Pharmaceuticals, LLC30
尚未招募
4 期
Post marketing study to evaluate the Safety and Efficacy of Wikoryl Drops in infants (1 year)CTRI/2021/12/039024Alembic Pharmaceuticals Limited
已完成
4 期
Active post marketing surveillance (PMS) to evaluate the safety and efficacy of Sinarest Oral Drops in infants of common cold or allergic rhinitis.CTRI/2021/11/037913Centaur Pharmaceuticals Pvt Ltd415